The soluble transferrin receptor reflects tumor load in chronic lymphocytic leukemia

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 10, 2007, Pages 1313-1318

  Metzgeroth, Georgia ^a   Schultheis, Beate ^a   Kuhn, Christian ^a   Dorn Beineke, Alexandra ^b   Larosée, Paul ^a   Hehlmann, Rüdiger ^a   Hastka, Jan ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chronic lymphocytic leukemia; Soluble transferrin receptor; Tumor load

Indexed keywords

TRANSFERRIN RECEPTOR;

ADULT; AGED; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEMOLYSIS; HUMAN; IRON DEFICIENCY; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; RECEPTORS, TRANSFERRIN; SOLUBILITY; TUMOR BURDEN;

EID: 35048893248     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.287     Document Type: Article

References (25)

1. Kohgo Y, Nishisato T, Kondo H, Tsushima N, Niitsu Y, Urushizaki I. Circulating transferrin receptor in human serum. Br J Haematol 1986;64:277-81.
2. Kohgo Y, Niitsu Y, Kondo H, Kato J, Tsushima N, Sasaki K, et al. Serum transferrin receptor as a new index of erythropoiesis. Blood 1987;70:1955-8.
3. Punnonen K, Irjala K, Rajamaki A. Iron-deficiency anemia is associated with high concentrations of transferrin receptor in serum. Clin Chem 1994;40:774-6.
4. Cook JD, Skikne BS, Baynes RD. Serum transferrin receptor. Annu Rev Med 1993;44:63-74.
5. Metzgeroth G, Adelberger V, Dorn-Beineke A, Kuhn C, Schatz M, Maywald O, et al. Soluble transferrin receptor and zinc protoporphyrin - competitors or efficient partners? Eur J Haematol 2005;75:309-17.
6. Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta 2003;329:9-22.
7. Klemow D, Einsphar D, Brown TA, Flowers CH, Skikne BS. Serum transferrin receptor measurements in hematologic malignancies. Am J Hematol 1990;34:193-8.
8. Beguin Y, Lampertz S, De Groote D, Igot D, Malaise M, Fillet G. Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in serum of patients with chronic lymphocytic leukemia. Leukemia 1993;7:2019-25.
9. Huebers HA, Beguin Y, Pootrakul P, Einspahr D, Finch CA. Intact transferrin receptors in human plasma and their relation to erythropoiesis. Blood 1990;75:102-7.
10. O'Brien S, del Giglio A, Keating M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 1995;85:307-18.
11. Binet JL, Lepoprier M, Dighiero G, Charron D, d'Athis P, Vaugier G, et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 1977;40:855-64.
12. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-34.
13. Binet JL, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G, et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 2006;107:859-61.
14. Hallek M, Wanders L, Ostwald M, Busch R, Senekowitsch R, Stern S, et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 1996;22:439-47.
15. Keating MJ, O'Brien S, McLaughlin P, Dimopoulos M, Gandhi V, Plunkett W, et al. Clinical experience with fludarabine in hemato-oncology. Hematol Cell Ther 1996;38(Suppl 2):S83-91.
16. Reinisch W, Willheim M, Hilgarth M, Gasche C, Mader R, Szepfalusi S, et al. Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. J Clin Oncol 1994;12:2146-52.
17. Sarfati M, Chevret S, Chastang C, Biron G, Stryckmans P, Delespesse G, et al. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 1996;88:4259-64.
18. Seiler T, Döhner H, Stilgenbauer S. Risk stratification in chronic lymphocytic leukemia. Semin Oncol 2006;33:186-94.
19. Fields B, Sollinger H, Glass N, Carlson I, Belzer F. Beta-2-microglobulin versus creatinine as the sole indicator of rejection in renal transplants. Transplant Proc 1984;16:1591-3.
20. Yoshikawa T, Nanba T, Kato H, Hori K, Inamoto T, Kumagai S, et al. Soluble Fc epsilon RII/C23 in patients with autoimmune disease and Epstein-Barr virus-related disorder: analysis by ELSIA fpr soluble Fc epsilon RII/CD23. Immunomethods 1994;4:71.
21. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, et al. National Cancer Institute - sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-7.
22. Knospe WH, Loeb V Jr, Huguley CM Jr. Proceedings: bi-weekly chlorambucil treatment of chronic lymphocytic leukemia. Cancer 1974;33:555-62.
23. Metzgeroth G, Bergmann J, Schlegel F, Emig M, Maywald O, Eichler H, et al. Evaluation of haematopoietic recovery after autologous blood stem cell transplantation by soluble transferrin receptor. Onkologie 2002;25:100.
24. Testa U, Rutella S, Martucci R, Scambia G, D'Onofrio G, Pierelli L, et al. Autologous stem cell transplantation: evaluation of erythropoietic reconstitution by highly fluorescent reticulocyte counts, erythropoietin, soluble transferrin receptors, ferritin, TIBC and iron dosages. Br J Haematol 1997;96:762-75.
25. Barnett D, Wilson GA, Lawrence AC, Buckley GA. Transferrin receptor expression in the leukaemias and lymphoproliferative disorders. Clin Lab Haematol 1987;9:361-70.